Cardiomyocytes
hES-CMC™ - Cardiomyocyte Clusters
Fresh cardiomyocytes in a 3D tissue-like format, ready for in vitro use
hES-CMC™ are spontaneously beating hES cell derived cardiomyocytes in a cluster format, ranging in size from 200-300μm in diameter. The cells exhibit specific markers and functional similarities to adult human cardiac myocytes. hES-CMC™ are excellent in vitro tools for studies of human cardiomyocyte function and for cardiac safety pharmacology assays. hES-CMC™ are available from two different hESC lines, SA002 and SA121, both lines registered at the European hESC registry.
Data from several global expression profiling experiments from hES cell derived cardiomyocytes are available for our customers via our Cellartis Customer Login.
Applications
|
Typical Assays
|
Advantages
|
|
|
|||||||||||||||||||||||||||||
REFERENCES
1. Norström A et al. Molecular and pharmacological properties of human embryonic stem cell derived cardiomyocytes.
Exp Biol Med. 2006 Dec;231(11):1753-62.
“This study describes differentiation of hES cells into cardiomyocyte-like cells. Spontaneously contracting cell clusters were isolated and characterized. Electron microscopy analysis demonstrated Z discs and tight junctions in the hES cell-derived cardiomyocytes, and by immunohistochemical analysis the expression of cardiac-specific markers (cTnI and cMHC) was detected. Pharmacological stimulation of the cells resulted in responses indicative of functional adrenergic and muscarinic receptor coupling systems.”
2. Meyer T et al. New Cell Models & Assays in Cardiac Safety Profiling.
Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):507-17.
“This review discusses established as well as innovative assays and cell models used to investigate drug-induced prolongation of the QT interval. Especially, novel opportunities using stem cell derived cardiomyocytes are highlighted.”
3. Sartipy P et al . The application of human embryonic stem cell technologies to drug discovery.
Drug Discov Today 2007 Sep;12(17-18):688-99.
“A review paper discussing the use of stem cell derived functional cells, including cardiomyocytes, for in vitro applications in drug discovery.”
4. Synnergren J et al. Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells.
Stem Cells. 2008 Jul;26(7):1831-40.
“In this study, microarrays were used to analyze the global gene expression profile of isolated hES-CMC. Differentially expressed genes were also classified according to their Gene Ontology annotation. The results demonstrated that the hES-CMC display high similarities, on a molecular level, to human heart tissue. “
5. Steel D et al. Cardiomyocytes derived from human embryonic stem cells – Characteristics and utility for drug discovery.
Curr Opin in Drug Discov and Dev, 2009 Jan;12(1):133-140.
“This review discusses recent developments and improvements of hES cell-derived cardiomyocytes and provides some examples of how these cells are beginning to find practical use in drug discovery and development.”
6. Jonsson MKB et al. Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell derived cardiomyocytes.
Expert Opin Drug Discov 2009 4(4):357-372.
“In this review, contemporary drug discovery models and their characteristics for cardiac efficacy testing and safety assessment are discussed. Additionally, various sources of stem cells and how these cells could potentially improve early screening and safety models are evaluated.”
7. Vidarsson H et al. Differentiation of Human Embryonic Stem Cells to Cardiomyocytes for In Vitro and In Vivo Applications.
Stem Cell Rev. 2010 Mar;6(1):108-20.
“In this review, recent strategies for the generation of cardiomyocytes from hES cells are discussed. In addition, the features of the differentiated cells are recapitulated, as well as some in vitro applications for the cells. Opportunities in the area of cardiac regenerative medicine are also illustrated.”
8. Jonsson MKB et al. Quantified Proarrhythmic Potential of Selected Human Embryonic Stem Cell-derived Cardiomyocytes.
Stem Cell Research, Volume 4, Issue 2, March 2010
“This study describes the selection of human ventricular-like embryonic stem cell-derived cardiomyocytes following a standardized protocol. Also, their arrhythmogenic response was quantified and compared to a contemporary used rabbit Purkinje Fiber model.”
